leflunomide has been researched along with Scleroderma, Systemic in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 7.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 3.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SY | 1 |
| Lee, SW | 1 |
| Chung, WT | 1 |
| Oliveira, AC | 1 |
| Mota, LM | 1 |
| Santos-Neto, LL | 1 |
| Simões, M | 1 |
| Martins-Filho, OA | 1 |
| Tauil, PL | 1 |
| Gordeev, AV | 1 |
| Mutovina, ZIu | 1 |
| Nasankaeva, EK | 1 |
| Sebastiani, M | 1 |
| Giuggioli, D | 1 |
| Vesprini, E | 1 |
| Caruso, A | 1 |
| Ferri, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388] | 600 participants (Actual) | Interventional | 2018-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for leflunomide and Scleroderma, Systemic
| Article | Year |
|---|---|
Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report.
Topics: Arthritis, Rheumatoid; Calcinosis; Female; Humans; Immunosuppressive Agents; Leflunomide; Middle Age | 2018 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat | 2015 |
[Effective treatment of systemic sclerosis with leflunomide].
Topics: Aged; Female; Humans; Isoxazoles; Leflunomide; Scleroderma, Systemic; Treatment Outcome | 2005 |
Successful treatment with leflunomide of arthritis in systemic sclerosis patients.
Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; Sclero | 2006 |